Antibodies-to-Infliximab Accelerate Clearance While D
Immunogenicity and Recaptures Clinical Response in P

Alimentary Pharmacology and Therapeutics

55, 593-603

DOI: 10.1111/apt.16733

Citation Report

#	Article	IF	Citations
1	Letter: Immunogenicity Is Not the Root Cause for Loss of Response to Anti-TNF Agents in Patients With IBD in TDM Era. Alimentary Pharmacology and Therapeutics, 2022, 55, 885-886.	7.7	4
2	Reply. Gastroenterology, 2022, 163, 1124-1125.	12.5	0
3	Prognostication in Inflammatory Bowel Disease. Frontiers in Medicine, 2022, 9, 1025375.	3.7	12
4	A Systematic Review on the Interest of Drug-Tolerant Assay in the Monitoring of Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2023, 17, 633-643.	8.8	15
5	Real World Population Pharmacokinetic Study in Children and Young Adults With Inflammatory Bowel Disease Discovers Novel Blood and Stool Microbial Predictors of Vedolizumab Clearance. Alimentary Pharmacology and Therapeutics, 2023, 57, 524-539.	7.7	26
6	Association Between HLA DNA Variants and Long-Term Response to Anti-TNF Drugs in a Spanish Pediatric Inflammatory Bowel Disease Cohort. International Journal of Molecular Sciences, 2023, 24, 1797.	5.9	16
7	Influence of HLADQA1*05 Genotype in Adults With Inflammatory Bowel Disease and Anti-TNF Treatment With Proactive Therapeutic Drug Monitoring: A Retrospective Cohort Study. Inflammatory Bowel Diseases, 2023, 29, 1586-1593.	5.5	26
8	Immunomodulator Comedication Promotes the Reversal of Anti-Drug Antibody-Mediated Loss of Response to Anti-TNF Therapy in Inflammatory Bowel Disease. International Journal of Colorectal Disease, 2023, 38, 1-17.	3.1	14
9	HLA-DQA1∗05 Genotype and Immunogenicity to Tumor Necrosis Factor-α Antagonists: A Systematic Review and Meta-Analysis. Clinical Gastroenterology and Hepatology, 2023, 21, 3019-3029.e5.	10.5	46
10	Can Proactive Therapeutic Drug Monitoring Overcome Pharmacogenomic-Associated Immunogenicity to Anti-Tumor Necrosis Factor Agents?. Clinical Gastroenterology and Hepatology, 2024, 22, 200-201.	10.5	1
11	Safety Summary of Pediatric Inflammatory Bowel Disease Therapies. Gastroenterology Clinics of North America, 2023, 52, 535-548.	3.6	3
12	The Role of Therapeutic Drug Monitoring in Children. Gastroenterology Clinics of North America, 2023, 52, 549-563.	3.6	6
13	Choosing the Right Therapy at the Right Time for Pediatric Inflammatory Bowel Disease: Does Sequence Matter. Gastroenterology Clinics of North America, 2023, 52, 517-534.	3.6	1
14	Adalimumab Clearance, Rather Than Trough Level, May Have Greatest Relevance to Crohn's Disease Therapeutic Outcomes Assessed Clinically and Endoscopically. Journal of Crohn's and Colitis, 2024, 18, 212-222.	8.8	18
15	Precision Dosing of Anti-TNF Therapy in Pediatric Inflammatory Bowel Disease. Current Gastroenterology Reports, 2023, 25, 323-332.	4.9	14
16	Infliximab in Chronic Non-Infectious Paediatric Uveitis Refractory to Previous Biologic Therapy. Eye, 2024, 38, 1-6.	4.0	21
17	Biomarkers That Predict Crohn's Disease Outcomes. Journal of the Canadian Association of Gastroenterology, 2024, 7, 59-67.	2.9	11
18	The Combination of Predictive Factors of Pharmacokinetic Origin Associates With Enhanced Disease Control During Treatment of Pediatric Crohn's Disease With Infliximab. Pharmaceutics, 2023, 15, 2408.	7.5	10

#	Article	IF	Citations
19	Drug Clearance in Patients With Inflammatory Bowel Disease Treated With Biologics. Journal of Clinical Medicine, 2023, 12, 7132.	3.8	49
20	Effectiveness of Strategies to Suppress Antibodies to Infliximab in Pediatric Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology and Nutrition, 2024, 78, 57-67.	3.3	6
21	Precision Medicine in Inflammatory Bowel Disease. Precision Clinical Medicine, 2023, 6, pbad033.	4.8	41
22	Infliximab Monotherapy vs Combination Therapy for Pediatric Crohn's Disease Exhibit Similar Pharmacokinetics. Inflammatory Bowel Diseases, 2024, 30, 1678-1685.	5.5	9
23	Impact of HLA-DQA1*05 Genotype in Immunogenicity and Failure to Treatment With Tumour Necrosis Factor-α Antagonists in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Journal of Crohn's and Colitis, 2024, 18, 1034-1052.	8.8	21
24	From Dose to Exposure: Shifting the Paradigm of Pediatric Clinical Pharmacology Research and Education. Clinical Pharmacology and Therapeutics, 2024, 116, 515-517.	5.3	3
25	Challenges in IBD Research 2024: Pragmatic Clinical Research. Inflammatory Bowel Diseases, 2024, 30, S55-S66.	5.5	7
26	Is Therapeutic Drug Monitoring a Dancing Partner for TNF-α Inhibitors in Real-World Practice? Answers From an Updated Systematic Review and Meta-Analysis. Expert Review of Clinical Pharmacology, 2024, 17, 1-14.	3.6	5
27	HLA DQA1*05 and Risk of Anti-TNF Treatment Failure and Anti-Drug Antibody Development in Children With Crohn's Disease: HLA DQA1*05 and Pediatric Crohn's Disease. American Journal of Gastroenterology, 2025, 120, 10.14309/ajg.0000000000003135.	5.8	6
28	Integrating Early Response Biomarkers in Pharmacokinetic Models: A Novel Method to Individualize the Initial Infliximab Dose in Patients With Crohn's Disease. Clinical and Translational Science, 2025, 18, e70086.	4.1	5
29	North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Position Paper on the Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology and Nutrition, 2025, 81, 1100-1117.	3.3	22
30	Overcoming Anti-Infliximab Antibodies and Maintaining Infliximab Achieves Superior Durability and Outcome Compared to Switching to Adalimumab. Digestive and Liver Disease, 2025, 57, 2128-2134.	4.4	1
31	Therapeutic Drug Monitoring in Special Circumstances in Inflammatory Bowel Disease. Journal of Clinical Medicine, 2025, 14, 7956.	3.8	3
32	Recent Developments in Biomarker Guided Therapy for Crohn's Disease. Expert Review of Gastroenterology and Hepatology, 2025, 19, 1241-1255.	3.5	2
33	Higher Anti-Drug Antibody Levels to Anti-Tumor Necrosis Factor Therapies Are Associated With Treatment Failure in Patients With Inflammatory Bowel Disease. Journal of Clinical Medicine, 2026, 15, 547.	3.8	2
34	Determination of Correlation of Clearance With Clinical Outcomes for Inflammatory Bowel Disease. World Journal of Gastroenterology, 2026, 32, 113505.	5.9	0
35	Genomic Impacts of Biological Exposures. Journal of Developmental Biology, 2026, 14, 12.	2.7	0
36	Lower Drug Clearance of Adalimumab Is Associated With Proactive Therapeutic Drug Monitoring and Mucosal Healing in Patients With Inflammatory Bowel Disease. European Journal of Gastroenterology and Hepatology, 2026, 38, 1030-1035.	2.1	1

#	Article	IF	Citations
37	Impact of Proactive Therapeutic Drug Monitoring on Infliximab Maintenance Therapy and Clinical Outcomes in Pediatric Inflammatory Bowel Disease: A Randomized Controlled Trial and Review of Literature. Gastro Hep Advances, 2026, 5, 100953.	2.4	0
38	Is Routine Monitoring of TNF-α Inhibitor Levels and Antibodies in Pediatric IBD Justified in the Era of Personalized Medicine. Journal of Clinical Medicine, 2026, 15, 4098.	3.8	0
39	Impact of Repeated Antigen Exposure on Humoral Tolerance: Antidrug Antibodies After Single-Dose Versus Multi-Dose Adalimumab. BioDrugs, 2026, 40, 747-757.	9.1	1
40	Aminosalicylate Use Increases Corticosteroid Exposure and Decreases Biologic Durability in Pediatric Crohn's Disease. Clinical Gastroenterology and Hepatology, 2026, .	10.5	1
41	Switching Between Anti-TNFs and Other Biologic Drugs in Paediatric Inflammatory Bowel Disease: A Narrative Review and Practical Clinical Guide. Journal of Inflammation Research, 2026, 19, 1-24.	4.6	0
42	Gradient Boosting Machine-Based Prognostic Model With SurvSHAP Analysis for Predicting Secondary Loss of Response to Infliximab Therapy in Crohn's Disease. Drug Design, Development and Therapy, 2026, 20, 1-24.	6.2	0
43	From ADA Positivity to Clinical Decision: A Context-of-Use Framework for Reflex Testing, Sampling Frequency and Stopping Rules in Immunogenicity Assessment. Bioanalysis, 2026, 18, 1-13.	1.6	0
44	Switching From Intravenous to Subcutaneous Infliximab in Children With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Current Gastroenterology Reports, 2026, 28, 34.	4.9	0
45	Baseline Clearance and Early Troughs Identify Candidates for Early Therapeutic Drug Monitoring During Infliximab Induction in Inflammatory Bowel Disease. Alimentary Pharmacology and Therapeutics, 2026, .	7.7	0